MULTIMODAL DIAGNOSTICS IN GLIOBLASTOMA: A COMPREHENSIVE REVIEW

Authors

  • Ikromov Ozodbek Ravshan ugl Author
  • Saydullayeva Maftuna Uchqun kizi Author
  • Axmediva Surayyo Nurali kizi Author

Keywords:

Glioblastoma (GBM), Multimodal MRI, Perfusion-Weighted Imaging (PWI), Diffusion-Weighted Imaging (DWI), Amino Acid PET, IDHwildtype, MGMT Promoter Methylation, WHO CNS5 Classification, Immunohistochemistry (IHC), Molecular Diagnostics.

Abstract

Glioblastoma (GBM) is a highly aggressive and heterogeneous primary brain tumor. Accurate diagnosis is essential for effective treatment planning and distinguishing true tumor progression from treatmentinduced pseudoprogression.

References

1. Cha, S. (2017). Multi-parametric MRI in glioma imaging and radiomics.

Neuro-Oncology, 19(Suppl 2), ii38–ii50.

2. Kickingereder, P., et al. (2016). Radiomic MRI signature reveals three

distinct subtypes of glioblastoma with different clinical and molecular

characteristics. Clinical Cancer Research, 22(11), 2751–2761.

3. Tsolaki, E., Papadaki, E., & Karantanas, A. (2021). Advanced MRI for

Glioblastoma: Clinical Utility and Future Directions. AJR. American Journal

of Roentgenology, 216(5), 1209–1221.

4. Essig, M., et al. (2013). Perfusion MRI: Current concepts and clinical

applications in gliomas. Radiology, 268(2), 342–356.

5. Pope, W. B., et al. (2005). MR imaging correlates of survival in patients

with high-grade gliomas. AJNR. American Journal of Neuroradiology,

26(10), 2466–2474.

6. Molina, D. C., Ambrosi, C., & Weller, M. (2021). Machine learning and

glioma diagnostics: Emerging concepts. The Lancet Digital Health, 3(7),

e409–e410.

7. Bette, S., et al. (2017). Radiogenomics of glioblastoma: Machine learningbased MRI texture analysis vs. molecular genetics. Journal of NeuroOncology, 135(3), 633–640.

8. Yan, H., et al. (2009). IDH1 and IDH2 mutations in gliomas. The New

England Journal of Medicine (NEJM), 360(8), 765–773.

9. Kresak, J. L., & Price, S. J. (2018). Diffusion MR imaging in high-grade

gliomas: A diagnostic and monitoring tool. Neuro-Oncology Practice, 5(4),

247–258.

10.Ellingson, B. M. (2015). Prognostic imaging biomarkers in glioblastoma.

AJNR. American Journal of Neuroradiology, 36(6), 835–840.

11.Lin, E. L., et al. (2017). MGMT promoter methylation and radiogenomic

signatures in glioblastoma. Neuro-Oncology, 19(9), 1270–1279.

12.Miller, A. M., et al. (2019). Tracking tumor evolution via circulating tumor

DNA in glioma. Nature Medicine, 25(10), 1459–1462.

13.Wang, Y., et al. (2015). Detection of tumor-derived DNA in cerebrospinal

fluid of glioma patients. Science Translational Medicine, 7(304), 304ra136.

14.Zhang, R., et al. (2020). Noninvasive prediction of MGMT promoter

methylation in glioblastoma using radiomics. European Radiology, 30(11),

6210–6219.

15.Park, J. E., et al. (2019). Deep learning MRI predicts IDH and 1p/19q

status in gliomas. Radiology, 291(3), 745–754.

Published

2026-05-11